Navigation Links
Research identifies type of vaccine that holds promise in protecting against TB
Date:10/19/2008

ST. LOUIS -- Researchers are one step closer to finding a vaccine that better protects against tuberculosis. An investigational vaccine for TB tested at Saint Louis University appears likely to offer significantly better protection against the potentially fatal disease than the one in current use.

"Not only was it as safe as the standard vaccine, it induced a better immune response, which suggests it will be more effective at protecting against tuberculosis," said Daniel Hoft, M.D., Ph.D., director of the division of immunobiology at Saint Louis University School of Medicine and lead author of the study.

The investigational vaccine is made from a weakened TB germ from one of the strains of the current tuberculosis vaccine, which was created more than 75 years ago. The new "recombinant" vaccine uses an antigen a secreted protein from a virulent strain of tuberculosis to help focus the immune system on blocking aggressive and deadly TB organisms.

In this phase I clinical trial, researchers vaccinated a total of 35 study participants. The standard TB vaccine -- called Bacille Calmette-Gurin (BCG) -- was given to 17 study participants, and 18 study participants received the investigational recombinant BCG vaccine.

Researchers compared five immune functions induced by the vaccines and found that the investigational vaccine induced more powerful responses that are important for protection against tuberculosis. The investigational vaccine also was safe and well tolerated.

The research demonstrated that the concept of using a recombinant vaccine holds promise in being able to better protect people from tuberculosis. This vaccine will not be tested further because it uses an antibiotic resistant gene that scientists want to keep out of the environment. However research in this area will continue as scientists test a similar recombinant BCG vaccine that expresses the same and additional key TB antigens that is expected to be even more potent than the one just studied and does not include the antibiotic resistant gene, Hoft said.

"A new vaccine theoretically could not only protect against the overwhelming growth of TB organisms, but could kill residual organisms after a person has become infected. That's the hope," Hoft said.

It's critical to find a better vaccine, Hoft said. Tuberculosis strikes developing nations hardest, infecting one in three people worldwide. Nearly 8 million new cases of TB develop each year, and 2 million die from the infectious disease.

"These staggering statistics persist despite the availability of a tuberculosis vaccine," Hoft said. "New vaccines are urgently needed to reduce this immense burden of TB."

The World Health Organization recommends the current BCG vaccine for infants in developing countries shortly after they are born. The vaccine induces partial protection, and vaccinated children who contract a tuberculosis infection have a less severe illness. The current vaccine is about 70 percent protective against deaths or meningitis from tuberculosis and about 50 percent protective against pulmonary tuberculosis.


'/>"/>

Contact: Nancy Solomon
solomonn@slu.edu
314-977-8017
Saint Louis University
Source:Eurekalert

Related biology news :

1. Researchers identify Achilles heel of common childhood tumor
2. Waste from gut bacteria helps host control weight, UT Southwestern researchers report
3. Salk researchers successfully reprogram keratinocytes attached to a single hair
4. Scripps research team sheds light on immune system suppression
5. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
6. MU brain imaging center provides research for autism, schizophrenia and Parkinsons disease
7. Cost-effective farm waste-to-energy technology focus of research
8. Alzheimers disease research attracts first partner
9. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
10. Researchers identify promising gene target for neuroblastoma therapy
11. Salk researcher Terry Sejnowski elected to Institute of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: